Author: "Meric-Bernstam F" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Meric-Bernstam F"' showing total 1,206 results

Start Over Author "Meric-Bernstam F"

1,206 results on '"Meric-Bernstam F"'

1. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Author: Curigliano, G., Jimenez, M.M., Shimizu, T., Keam, B., Meric-Bernstam, F., Rutten, A., Glaspy, J., Schuler, P.J., Parikh, N.S., Ising, M., Hassounah, N., Wu, J., Leyk, M., Chen, X., Burks, H., Chaudhury, A., Otero, J., and Cabanas, E.Garralda
Published: 2024
Full Text: View/download PDF

2. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Author: Mosele, M.F., Westphalen, C.B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., Czarnecka, A.M., Meric-Bernstam, F., Michiels, S., Miller, R., Normanno, N., Reis-Filho, J., Remon, J., Robson, M., Rouleau, E., Scarpa, A., Serrano, C., Mateo, J., and André, F.
Published: 2024
Full Text: View/download PDF

3. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors

Author: Gouda, M.A., Shunyakova, J., Naing, A., Dumbrava, E., Hong, D.S., Yuan, Y., Yang, P., Myers, A., Liang, Y., Peng, J., Karp, D., Tsimberidou, A.M., Rodon, J., Yap, T.A., Piha-Paul, S.A., Meric-Bernstam, F., and Fu, S.
Published: 2024
Full Text: View/download PDF

4. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study

Author: Phadnis, S., Wang, X., Daw, N.C., Herzog, C.E., Subbiah, I.M., Zaky, W., Gouda, M.A., Morani, A.C., Amini, B., Harrison, D.J., Piha-Paul, S.A., Meric-Bernstam, F., Gorlick, R., Schwartz, C.L., and Subbiah, V.
Published: 2023
Full Text: View/download PDF

5. HER2-low expression in patients with advanced or metastatic solid tumors

Author: Uzunparmak, B., Haymaker, C., Raso, G., Masciari, S., Wang, L., Lin, H., Gorur, A., Kirby, B., Cimo, A.-M., Kennon, A., Ding, Q., Urschel, G., Yuan, Y., Feng, G., Rizvi, Y., Hussain, A., Zhu, C., Kim, P., Abbadessa, G., Subbiah, V., Yap, T.A., Rodon, J., Piha-Paul, S.A., Meric-Bernstam, F., and Dumbrava, E.E.
Published: 2023
Full Text: View/download PDF

6. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.

Author: Meric-Bernstam, F, Hainsworth, J, Spigel, D, Bose, R, Burris, H, Sweeney, C, Beattie, M, Blotner, S, Schulze, K, Cuchelkar, V, Swanton, C, Bowles, D, Kurzrock, Razelle, and Kang, Hyunseok
Subjects: HER2-positive, advanced salivary gland carcinoma, molecular profiling, pertuzumab, targeted therapy, trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carcinoma, Humans, Molecular Targeted Therapy, Receptor, ErbB-2, Salivary Gland Neoplasms, Salivary Glands, Trastuzumab
Abstract: BACKGROUND: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. PATIENTS AND METHODS: MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR). RESULTS: As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred. CONCLUSIONS: Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Published: 2020

7. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Author: Kurzrock, R, Bowles, DW, Kang, H, Meric-Bernstam, F, Hainsworth, J, Spigel, DR, Bose, R, Burris, H, Sweeney, CJ, Beattie, MS, Blotner, S, Schulze, K, Cuchelkar, V, and Swanton, C
Subjects: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carcinoma, Humans, Molecular Targeted Therapy, Receptor, ErbB-2, Salivary Gland Neoplasms, Salivary Glands, Trastuzumab, advanced salivary gland carcinoma, targeted therapy, HER2-positive, pertuzumab, trastuzumab, molecular profiling, Receptor, erbB-2, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract: BackgroundSystemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics.Patients and methodsMyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR).ResultsAs of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred.ConclusionsOverall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Published: 2020

8. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

Author: Gouda, M.A., Polivka, J., Huang, H.J., Treskova, I., Pivovarcikova, K., Fikrle, T., Woznica, V., Dustin, D.J., Call, S.G., Meric-Bernstam, F., Pesta, M., and Janku, F.
Published: 2022
Full Text: View/download PDF

9. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

Author: Dumbrava, E.E., Call, S.G., Huang, H.J., Stuckett, A.L., Madwani, K., Adat, A., Hong, D.S., Piha-Paul, S.A., Subbiah, V., Karp, D.D., Fu, S., Naing, A., Tsimberidou, A.M., Moulder, S.L., Koenig, K.H., Barcenas, C.H., Kee, B.K., Fogelman, D.R., Kopetz, E.S., Meric-Bernstam, F., and Janku, F.
Published: 2021
Full Text: View/download PDF

10. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

Author: Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., and Subbiah, V.
Published: 2021
Full Text: View/download PDF

11. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Author: Subbiah, V., Shen, T., Terzyan, S.S., Liu, X., Hu, X., Patel, K.P., Hu, M., Cabanillas, M., Behrang, A., Meric-Bernstam, F., Vo, P.T.T., Mooers, B.H.M., and Wu, J.
Published: 2021
Full Text: View/download PDF

12. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

Author: Mosele, F., Remon, J., Mateo, J., Westphalen, C.B., Barlesi, F., Lolkema, M.P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., Wagle, N., Stenzinger, A., Bonastre, J., Bayle, A., Michiels, S., Bièche, I., Rouleau, E., Jezdic, S., Douillard, J-Y., Reis-Filho, J.S., Dienstmann, R., and André, F.
Published: 2020
Full Text: View/download PDF

13. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

Author: Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K.A., Matos, I., and Arkenau, H.-T.
Published: 2020
Full Text: View/download PDF

14. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Author: Liu, X, George, GC, Tsimberidou, AM, Naing, A, Wheler, JJ, Kopetz, S, Fu, S, Piha-Paul, SA, Eng, C, Falchook, GS, Janku, F, Garrett, C, Karp, D, Kurzrock, R, Zinner, R, Raghav, K, Subbiah, V, Hess, K, Meric-Bernstam, F, Hong, DS, and Overman, MJ
Subjects: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Clinical Research, Colo-Rectal Cancer, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cetuximab, Colorectal Neoplasms, Disease-Free Survival, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Panitumumab, Proto-Oncogene Proteins p21(ras), Retreatment, Anti-EGFR treatment, KRAS-wt CRC, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract: BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty-nine KRAS exon 2-wild-type metastatic colorectal patients were retreated on phase I/II clinical trials containing anti-EGFR therapies after progressing on prior cetuximab or panitumumab. Response on prior anti-EGFR therapy was defined retrospectively per physician-records as response or stable disease ≥6 months. Multivariable statistical methods included a multiple logistic regression model for response, and Cox proportional hazards model for progression-free survival.ResultsRetreatment anti-EGFR agents were cetuximab (n = 76) or cetuximab plus erlotinib (n = 13). The median interval time between prior and retreatment regimens was 4.57 months (range: 0.46-58.7). Patients who responded to the prior cetuximab or panitumumab were more likely to obtain clinical benefit to the retreatment compared to the non-responders in both univariate (p = 0.007) and multivariate analyses (OR: 3.38, 95 % CI: 1.27, 9.31, p = 0.019). The clinical benefit rate on retreatment also showed a marginally significant association with interval time between the two anti-EGFR based therapies (p = 0.053). Median progression-free survival on retreatment was increased in prior responders (4.9 months, 95 % CI: 3.6, 6.2) compared to prior non-responders (2.5 months, 95 % CI, 1.58, 3.42) in univariate (p = 0.064) and multivariate analysis (HR: 0.70, 95 % CI: 0.43-1.15, p = 0.156).ConclusionOur data lends support to the concept of clonal evolution, though the clinical impact appears less robust than previously reported. Further work to determine which patients benefit from retreatment post progression is needed.
Published: 2015

15. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Author: Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., III, and Doebele, R.C.
Published: 2019
Full Text: View/download PDF

16. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

Author: Liu, L., Toung, J.M., Jassowicz, A.F., Vijayaraghavan, R., Kang, H., Zhang, R., Kruglyak, K.M., Huang, H.J., Hinoue, T., Shen, H., Salathia, N.S., Hong, D.S., Naing, A., Subbiah, V., Piha-Paul, S.A., Bibikova, M., Granger, G., Barnes, B., Shen, R., Gutekunst, K., Fu, S., Tsimberidou, A.M., Lu, C., Eng, C., Moulder, S.L., Kopetz, E.S., Amaria, R.N., Meric-Bernstam, F., Laird, P.W., Fan, J.-B., and Janku, F.
Published: 2018
Full Text: View/download PDF

17. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients

Author: Tevis, S. E., Bassett, R., Bedrosian, I., Barcenas, C. H., Black, D. M., Caudle, A. S., DeSnyder, S. M., Fitzsullivan, E., Hunt, K. K., Kuerer, H. M., Lucci, A., Meric-Bernstam, F., Mittendorf, E. A., Park, K., Teshome, M., Thompson, A. M., and Hwang, R. F.
Published: 2019
Full Text: View/download PDF

18. Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors

Author: Gouda, M.A., primary, Hu, M., additional, Cabanillas, M., additional, Wu, J., additional, Meric-Bernstam, F., additional, and Subbiah, V., additional
Published: 2023
Full Text: View/download PDF

19. 132P Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC)

Author: Valero, V., primary, Mouabbi, J., additional, Alonzo, H., additional, Ilheme, A. Nwosu, additional, Murthy, R., additional, Huang, X., additional, Qiao, W., additional, Patel, M., additional, Pohlmann, P.R., additional, Rauch, G., additional, Checka, C., additional, Hunt, K., additional, Tripathy, D., additional, Meric-Bernstam, F., additional, and Symmans, F., additional
Published: 2023
Full Text: View/download PDF

20. 33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models

Author: Meric-Bernstam, F., primary, Yuca, E., additional, Evans, K., additional, Zhao, M., additional, Raso, M.G., additional, Maejima, T., additional, Zheng, X., additional, Rizvi, Y., additional, Akcakanat, A., additional, Scott, S., additional, Wang, B., additional, Byers, L.A., additional, Tripathy, D., additional, Okajima, D., additional, and Damodaran, S., additional
Published: 2023
Full Text: View/download PDF

21. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

Author: Lesurf, R., Griffith, O.L., Griffith, M., Hundal, J., Trani, L., Watson, M.A., Aft, R., Ellis, M.J., Ota, D., Suman, V.J., Meric-Bernstam, F., Leitch, A.M., Boughey, J.C., Unzeitig, G., Buzdar, A.U., Hunt, K.K., and Mardis, E.R.
Published: 2017
Full Text: View/download PDF

22. High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

Author: Allenson, K., Castillo, J., San Lucas, F.A., Scelo, G., Kim, D.U., Bernard, V., Davis, G., Kumar, T., Katz, M., Overman, M.J., Foretova, L., Fabianova, E., Holcatova, I., Janout, V., Meric-Bernstam, F., Gascoyne, P., Wistuba, I., Varadhachary, G., Brennan, P., Hanash, S., Li, D., Maitra, A., and Alvarez, H.
Published: 2017
Full Text: View/download PDF

23. MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction

Author: Janku, F., Huang, H.J., Fujii, T., Shelton, D.N., Madwani, K., Fu, S., Tsimberidou, A.M., Piha-Paul, S.A., Wheler, J.J., Zinner, R.G., Naing, A., Hong, D.S., Karp, D.D., Cabrilo, G., Kopetz, E.S., Subbiah, V., Luthra, R., Kee, B.K., Eng, C., Morris, V.K., Karlin-Neumann, G.A., and Meric-Bernstam, F.
Published: 2017
Full Text: View/download PDF

24. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Author: Curigliano, G., Gómez Pardo, P., Meric-Bernstam, F., Conte, P., Lolkema, M.P., Beck, J.T., Bardia, A., Martínez García, M., Penault-Llorca, F., Dhuria, S., Tang, Z., Solovieff, N., Miller, M., Di Tomaso, E., and Hurvitz, S.A.
Published: 2016
Full Text: View/download PDF

25. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Author: Overman, M.J., Morris, V., Kee, B., Fogelman, D., Xiao, L., Eng, C., Dasari, A., Shroff, R., Mazard, T., Shaw, K., Vilar, E., Raghav, K., Shureiqi, I., Liang, L., Mills, G.B., Wolff, R.A., Hamilton, S., Meric-Bernstam, F., Abbruzzese, J., Morris, J., Maru, D., and Kopetz, S.
Published: 2016
Full Text: View/download PDF

26. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

Author: Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A.M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., Lara-Guerra, H., Litton, J., Arun, B., Eterovic, A.K., Aytac, U., Routbort, M., Subbiah, V., Janku, F., Davies, M.A., Kopetz, S., Mendelsohn, J., Mills, G.B., and Chen, K.
Published: 2016
Full Text: View/download PDF

27. Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Author: Gouda, M.A., Hu, M.I., Cabanillas, M.E., Wu, J., Meric-Bernstam, F., and Subbiah, V.
Published: 2023
Full Text: View/download PDF

28. 606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors.

Author: Meric-Bernstam, F., Naito, Y., Gaillard, S., Shimoi, T., Chung, V., Davis, A.A., Proia, T., Ayyoub, A., Kulkarni, M., Upadhyay, S., Miller, N., Luheshi, N., Varga, A., Oh, D-Y., and Mileshkin, L.
Subjects: *ANTIBODY-drug conjugates, *METASTASIS, *TUMORS
Published: 2024
Full Text: View/download PDF

29. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

Author: Yap, T.A., primary, Ngoi, N., additional, Dumbrava, E.E., additional, Karp, D.D., additional, Rodon Ahnert, J., additional, Fu, S., additional, Hong, D.S., additional, Naing, A., additional, Pant, S., additional, Piha-Paul, S.A., additional, Subbiah, V., additional, Tsimberidou, A.M., additional, Dufner, D., additional, Rhudy, J., additional, Gore, S., additional, Ivy, S.P., additional, Yuan, Y., additional, Westin, S.N., additional, Mills, G.B., additional, and Meric-Bernstam, F., additional
Published: 2022
Full Text: View/download PDF

30. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors

Author: Meric-Bernstam, F., primary, Eder, J.P., additional, Vandross, A., additional, Gara, M., additional, Gayle, S., additional, Pearson, P., additional, DeCillis, A., additional, and Tolcher, A., additional
Published: 2022
Full Text: View/download PDF

31. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations

Author: Ngoi, N., primary, Pilie, P.G., additional, Piha-Paul, S.A., additional, Dumbrava, E.E., additional, Fu, S., additional, Hong, D.S., additional, Karp, D.D., additional, Naing, A., additional, Pant, S., additional, Rodon Ahnert, J., additional, Subbiah, V., additional, Tsimberidou, A.M., additional, Salguero, C., additional, Brown, C.V., additional, Hoadley, W.E., additional, Johnson, A., additional, Yuan, Y., additional, Westin, S.N., additional, Meric-Bernstam, F., additional, and Yap, T.A., additional
Published: 2022
Full Text: View/download PDF

32. 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

Author: Friedman, C., primary, Swanton, C., additional, Spigel, D., additional, Bose, R., additional, Burris, H., additional, Yu, W., additional, Wang, Y., additional, Malato, J., additional, Price, R., additional, Darbonne, W., additional, Szado, T., additional, Schulze, K., additional, Sweeney, C., additional, Hainsworth, J., additional, Meric-Bernstam, F., additional, and Kurzrock, R., additional
Published: 2022
Full Text: View/download PDF

33. 485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials

Author: Ngoi, N.Y.L., primary, Lin, H., additional, Ileana Dumbrava, E.E., additional, Fu, S., additional, Karp, D., additional, Naing, A., additional, Pant, S., additional, Rodon, J., additional, Piha-Paul, S., additional, Subbiah, V., additional, Tsimberidou, A.M., additional, Campbell, E., additional, Urrutia, S., additional, Hong, D.S., additional, Meric-Bernstam, F., additional, Yuan, Y., additional, and Yap, T.A., additional
Published: 2022
Full Text: View/download PDF

34. 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study

Author: Ahn, E., primary, Rothe, M., additional, Mangat, P.K., additional, Garrett-Mayer, E., additional, Al Baghdadi, T., additional, Baron, A.D., additional, Krauss, J.C., additional, Balmanoukian, A.S., additional, Bauman, J.R., additional, Hameed, M.K., additional, Mileham, K.F., additional, Thota, R., additional, Gold, P.J., additional, Meric-Bernstam, F., additional, Powell, S.F., additional, Yang, E.S., additional, O'Lone, R., additional, Grantham, G.N., additional, Halabi, S., additional, and Schilsky, R.L., additional
Published: 2022
Full Text: View/download PDF

35. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

Author: Morris, V.K., Lucas, F. A. San, Overman, M.J., Eng, C., Morelli, M.P., Jiang, Z.-Q., Luthra, R., Meric-Bernstam, F., Maru, D., Scheet, P., Kopetz, S., and Vilar, E.
Published: 2014
Full Text: View/download PDF

36. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Author: Gonzalez-Angulo, A.M., Akcakanat, A., Liu, S., Green, M.C., Murray, J.L., Chen, H., Palla, S.L., Koenig, K.B., Brewster, A.M., Valero, V., Ibrahim, N.K., Moulder-Thompson, S., Litton, J.K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M.J., Symmans, W.F., Sahin, A., Giordano, S.H., Pusztai, L., Do, K.-A., Mills, G.B., Hortobagyi, G.N., and Meric-Bernstam, F.
Published: 2014
Full Text: View/download PDF

37. Which threshold for ER positivity? a retrospective study based on 9639 patients

Author: Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., Bedrosian, I., Buzdar, A.U., Symmans, W.F., Crow, J.R., Bender, M., Shah, R.R., Hortobagyi, G.N., and Hunt, K.K.
Published: 2014
Full Text: View/download PDF

38. 367P Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer

Author: Rosen, E., Caswell-Jin, J., Berz, D., Mai, N., Fulgar, G., Densel, M., Chiang, G., Sperry, S., Warner, D., and Meric-Bernstam, F.
Published: 2024
Full Text: View/download PDF

39. 35P The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates

Author: Ma, J., Guo, X., Lee, C., Meric-Bernstam, F., Harismendy, O., Jubb, A., Kim, D., and Lackner, M.R.
Published: 2024
Full Text: View/download PDF

40. 690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors

Author: Powles, T.B., Bhatia, A.K., Burtness, B., Kogawa, T., Nishina, T., Nakayama, I., Fountzilas, C., Castillo, D.R., Mckean, M., Meric-Bernstam, F., Colombo, N., Smithy, J.W., Fayette, J., Chandra, S., Sternberg, D.W., Sullivan, K.H., Yueh, S., Clinthorne, G., Kudchadkar, R., and Hayashi, H.
Published: 2024
Full Text: View/download PDF

41. 754P Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)

Author: Shapira-Frommer, R., Sudo, K., Harano, K., Mileshkin, L., Perets, R., Song, M., Cohen, J., Huang, Y-F., Ambrose, H., Brier, T., Dosani, A., Fraenkel, P.G., Kmieciak, A., Mitchell, P., Myers, C., Wang, J., Odegbami, R.I., Sykes, A., Turner, S., and Meric-Bernstam, F.
Published: 2024
Full Text: View/download PDF

42. 714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study

Author: Oaknin, A., Ang, J.E., Rha, S.Y., Yonemori, K., Kristeleit, R., Lin, C-C., Satoh, T., Garcia, P. Estevez, Sendur, M.A.N., Rodríguez, L. Medina, Italiano, A., Lugowska, I., Ray-Coquard, I.L., Oza, A.M., Zhao, J.L., Gajavelli, S., Filant, J., Bodla, S., Janjigian, Y.Y., and Meric-Bernstam, F.
Published: 2024
Full Text: View/download PDF

43. 681TiP A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies

Author: Rosen, L.S., Azad, N., Costa, R., Meric-Bernstam, F., Alaoui, H., Jablons, D.M., Munster, P., and Hamilton, E.P.
Published: 2024
Full Text: View/download PDF

44. 669P CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors

Author: Lorusso, P., Meric-Bernstam, F., Hafez, N., Rodriguez Rivera, I.I., Tripathy, D., Wilks, S., Pearson, P., Needle, M.N., and Tolcher, A.W.
Published: 2024
Full Text: View/download PDF

45. 653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors

Author: Ng, M.C.H., Yong, W.P., Meric-Bernstam, F., Lentz, R.W., Srirangam, V., Cometa, J.R., Blanchard, S., Nellore, R., Tan, A., Lee, Y-A., Lim, J., Gan, S., Koh, C., Adanan, Q., Joy, J., Pendharkar, V., Yeong, J.P.S., and Diermayr, V.
Published: 2024
Full Text: View/download PDF

46. 638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center

Author: Tsimberidou, A.M., Fu, S., Hong, D.S., Piha-Paul, S.A., Naing, A., Rodon, J., Yap, T.A., Karp, D., Dumbrava, E.E., Heymach, J.V., Ajani, J.A., Cartwright, C., BecK, J., Andersen, C., Kahle, M., Vining, D., Ross, J.S., Chao, C., Berry, D.A., and Meric-Bernstam, F.
Published: 2024
Full Text: View/download PDF

47. 629P Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)

Author: Fu, S., Tsimberidou, A.M., Dumbrava, E.E., Yuan, Y., McLeod, S., Karp, D., Rodon, J., Yu, H., Peng, J., Daniel, L.M., Piha-Paul, S.A., Naing, A., and Meric-Bernstam, F.
Published: 2024
Full Text: View/download PDF

48. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

Author: Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, and Zinner R
Subjects: crizotinib, alk/ros1, met, pazopanib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, vegf, RC254-282
Abstract: Sarina A Piha-Paul,1 Ecaterina E Dumbrava,1 Binoj C Nair,1 Wendy Xiong,1 Li Xu,1 Rosa Mostorino,1 Vivek Subbiah,1 Nizar Tannir,2 Siqing Fu,1 Aung Naing,1 Filip Janku,1 Daniel D Karp,1 Shreyaskumar Patel,3 Najat C Daw,4 David Hong,1 Funda Meric-Bernstam,1,5,6 Ralph Zinner7 1Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Breast Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; 6The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 7Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USACorrespondence: Sarina A Piha-PaulInvestigational Cancer Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 455, Houston, TX, 77030, USATel +1 713-563-1055Fax +1 713-792-3535Email spihapau@mdanderson.orgBackground: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of crizotinib could augment the clinical efficacy of pazopanib.Methods: We evaluated the safety and responses in patients with advanced solid tumors treated with crizotinib and pazopanib.Results: Eighty-two patients (median age 53 years, range 18– 78 years) were enrolled. The median number of prior systemic therapies was 3 (range, 0– 8). We were able to dose escalate to dose level 8 (crizotinib 250 mg twice daily and pazopanib 800 mg daily) with no MTD identified. Grade 3 or 4 toxicities were seen in 32% of patients with the highest prevalence being fatigue (n=9, 11%), diarrhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) and ALT increased (n=2, 2%). Of the 82 patients, 61 (74%) had measurable disease by RECISTv1.1 and reached first restaging (6 weeks). Partial response (PR) was observed in 6/61 (10%) patients, and stable disease (SD) lasting ≥ 6 months was observed in 10/61 patients (16%) (total = 16/61 (26%) of patients with SD ≥ 6 months/PR).Conclusion: Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was the most tolerable dosing of the combination and can be used in future studies. We also observed moderate clinical activity in patients with advanced solid tumors that had received numerous prior therapies.Keywords: crizotinib, pazopanib, VEGF, ALK/ROS1, MET
Published: 2021

49. List of Contributors

Author: Abdel-Wahab, O., primary, Akcakanat, A., additional, Boyle, S.E., additional, Brabb, T., additional, Brayton, C., additional, Bruna, A., additional, Burgenske, D.M., additional, Cassidy, J.W., additional, Chateau-Joubert, S., additional, Cheng, W., additional, Chen, Y., additional, Colby, L.A., additional, Corwin, E., additional, de Stanchina, E., additional, Duchamp, O., additional, Eswaraka, J., additional, Evans, K.W., additional, Fang, B., additional, Fedele, C.G., additional, Fleming, J.B., additional, Fontaine, J.-J., additional, Giddabasappa, A., additional, Girard, E., additional, Hill, L.R., additional, Hirenallur-Shanthappa, D.K., additional, Ho, G.Y., additional, Inghirami, G., additional, Iritani, B.M., additional, Jiang, Y., additional, Kaffenberger, S.D., additional, Krivtsov, A., additional, Lawrence, M.G., additional, Liang, L., additional, Liu, J., additional, MacKeigan, J.P., additional, Marangoni, E., additional, Mattar, M., additional, Mercado-Uribe, I., additional, Meric-Bernstam, F., additional, Mills, G.B., additional, Niu, N., additional, Olson, J.M., additional, Paez-Arango, N., additional, Paz, K., additional, Pham, K., additional, Pillai, S.P.S., additional, Pizzi, M., additional, Poirier, J.T., additional, Ramírez, J.A., additional, Rios Perez, M.V., additional, Risbridger, G., additional, Russell, P.J., additional, Sathyan, P., additional, Scaltriti, M., additional, Schmechel, S.C., additional, Scott, C., additional, Scott, C.L., additional, Servely, J.-L., additional, Shackleton, M., additional, Simons, B.W., additional, Snyder, J., additional, Sood, A.K., additional, Strand, A.D., additional, Taylor, R., additional, Thompson-Iritani, S., additional, Tinkey, P.T., additional, Uthamanthil, R., additional, Wang, L., additional, Williams, E.D., additional, Yuca, E., additional, Zhang, J., additional, and Zhang, R., additional
Published: 2017
Full Text: View/download PDF

50. Modeling Breast Cancer Heterogeneity With Patient-Derived Xenografts

Author: Evans, K.W., primary, Paez-Arango, N., additional, Akcakanat, A., additional, Yuca, E., additional, and Meric-Bernstam, F., additional
Published: 2017
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

1,206 results on '"Meric-Bernstam F"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources